MFDS
- Marketing authorisation holder: OMEROS CORP
- Status: likely_approved
🇰🇷 Yartemlea in South Korea
Yartemlea (NARSOPLIMAB) regulatory status in South Korea.
Marketing authorisation
Yartemlea in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in South Korea
Frequently asked questions
Is Yartemlea approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Yartemlea in South Korea?
OMEROS CORP holds the South Korean marketing authorisation.